System for predicting liver inflammatory degree of chronic viral hepatitis B patient with alanine transaminase being less than two times of upper normal limit

Abstract

The invention aims to solve the problem that a non-invasive diagnosis method is hardly available for confirming the hepatic pathological state of people with alanine transaminase (ALT) being less than two times of an upper normal limit in the prior art, and provides a system for predicting a liver inflammatory degree of a chronic viral hepatitis B patient with alanine transaminase being less than two times of the upper normal limit. The system comprises a detection module, an Inf-index1 calculation module and a liver inflammatory degree prediction module, wherein the detection module is used for detecting hepatitis B core antibody content, glutamic oxalacetic transaminase content and albumin content in serum of the chronic viral hepatitis B patient with alanine transaminase being less than two times of the upper normal limit; the Inf-index1 calculation module is used for calculating Inf-index1 according to the hepatitis B core antibody content, the glutamic oxalacetic transaminase content and the albumin content; the liver inflammatory degree prediction module is used for predicting the liver inflammatory degree of the chronic viral hepatitis B patient with alanine transaminase being less than two times of the upper normal limit. As proved by clinical test, the system has high prediction accuracy on the inflammatory degree of the chronic viral hepatitis B patient with alanine transaminase being less than the double upper normal limit, and a novel method is provided for clinical diagnosis.

Description

technical field [0001] The invention relates to a system for predicting the degree of liver inflammation of patients with chronic hepatitis B whose alanine aminotransferase is less than twice the normal upper limit, and belongs to the field of biomedicine. Background technique [0002] In China, chronic infection of hepatitis B virus is a public health problem that seriously threatens the health of our people; according to the results of the national hepatitis B serum epidemiological survey in 2006, the HBsAg (hepatitis B surface antigen: infected Hepatitis B virus marker) carrier rate was 7.18%. According to this calculation, there are about 93 million people with chronic hepatitis B virus infection in my country, of which about 20 million are chronic hepatitis B patients. Without effective treatment, patients with chronic hepatitis B will progress to liver fibrosis and cirrhosis, and various life-threatening complications will occur. [0003] International and domestic g...

AI Technical Summary

Problems solved by technology

[0003] International and domestic guidelines use alanine aminotransferase (ALT), hepatitis B virus gene (HBVDNA), and hepatitis B antigen (HBe antigen) status as clinical indicators to measure whether hepatitis B is antiviral treatment; among them, ALT is the most commonly used clinically to judge liver damage, Serological indicators of liver inflammation (the gold standard is liver puncture); when the alanine aminotransferase in patients with hepatitis B is greater than or equal to twice the upper limit of normal (ALT ≥ 2 times), it is the standard of hepatitis activity, and antiviral treatment must be performed clinically; For hepatitis B patients whose alanine aminotransferase is less than twice the upper limit of normal (ALT<2 times), literature reports that about 30% of these patients have obvious liver fibrosis or moderate to se

Images